ABX 203

Drug Profile

ABX 203

Alternative Names: ABX-203; Anti-HBV therapeutic vaccine - Abivax/CIGB; Hepatitis B vaccine - CIGB; NASVAC

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Center for Genetic Engineering and Biotechnology; Wittycell
  • Developer Abivax; Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants; Natural killer cell receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatitis B

Most Recent Events

  • 01 Dec 2016 Abivax completes a phase-II/III trial in Hepatitis B in New Zealand and Australia (NCT02249988)
  • 26 Feb 2015 Phase-II/III clinical trials in Hepatitis B in New Zealand (unspecified route)
  • 31 Jul 2013 Heber Biotec and the Center for Genetic Engineering and Biotechnology complete a phase I trial in Hepatitis B in Cuba (Intranasal formulation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top